EI 001
Alternative Names: EI-001Latest Information Update: 02 Dec 2021
At a glance
- Originator Elixiron Immunotherapeutics
- Class Antivirals; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Vitiligo
- Discontinued Hepatitis B
Most Recent Events
- 02 Dec 2021 Discontinued - Preclinical for Hepatitis B in China (IV) (Elixiron Immunotherapeutics pipeline, December 2021)
- 02 Dec 2021 Elixiron Immunotherapeutics plans a phase I trial (In volunteers) (IV, Infusion) (NCT04994912)
- 01 Oct 2021 Phase-I clinical trials in Vitiligo (In volunteers) in Australia (IV,Infusion) (NCT04994912)